Biib stock price looking at sector multiples

Looking at sector multiples, BIIB stock price trades at a forward P/E of 13.8, which is below the biotech industry median. This valuation discount could attract value-oriented investors if growth catalysts materialize. Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases. Add Quiver Quantitative to your preferred sources on Google Earnings-per-share growth projections for Biogen this year remain in the 6–7% range, which underpins longer-term investor confidence in BIIB stock price stability despite short-term sector rotations.